Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Proxymetacaine and Fluorescein Minims
Proxymetacaine Minims
Quinidine		For hospital only use. All prescribing is retained by secondary care (Unlicensed)
Rabies immunoglobulin
Radium-223 (Xofigo®)	TA412 - Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases	Hospital only - NHSE commissioned
Ralititrexed injection		Hospital use only
Ranibizumab injection	TA294 - Aflibercept solution for injection for treating wet age-related macular degeneration TA297 - Ocriplasmin for treating vitreomacular traction TA298 - Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
Rasburicase injection
Raviciti (Glycerol phenylbutyrate liquid)
Ravulizumab (Ultomiris®)	TA710 - Ravulizumab for treating atypical haemolytic uraemic syndrome TA698 - Ravulizumab for treating paroxysmal nocturnal haemoglobinuria

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.